A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

January 1, 2023

Conditions

Diabetes

Interventions

DRUG

TG103 injection

TG103 injection, SC, once weekly

DRUG

Placebo

Placebo control, SC, once weekly

Trial Locations (1)

Gao Huanhuan, Beijingcun

All Listed Sponsors

lead

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

INDUSTRY